Survival curves for patients with systemic light chain amyloidosis stratified by hematologic response at six months

Patients in this international case series from seven centers were analyzed for survival at three months after beginning therapy based on metrics for hematologic response assessed at six months. In this series, 43.6 percent received oral melphalan and dexamethasone (MDex), 11.4 percent SCT, 22 percent immunomodulatory agent-based therapy, and 3 percent bortezomib and dexamethasone. Response criteria are CR (immunofixation negative and FLC normal); very good PR (very good partial; reduction in the dFLC to <40 mg/L); PR (partial; reduction in the dFLC by >50 percent); and NR (no response; less than PR).^[1]